A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Summary

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.

Timeline

Start

2018-01-30

Primary completion

2018-12-24

Completion

2019-07-29

Drugs

Indications